BioCentury | May 25, 2018
Emerging Company Profile

Universal ambitions

...time and cost of traditional vaccine development. Emergex launched in 2016 with IP acquired from Immunotope Inc....
...infection and now has long-term CD8+ memory,” Rademacher said. In a 2014 paper describing the Immunotope...
...2016 by Thomas Rademacher and Storme Moore-Thornicroft University collaborators: Undisclosed Corporate partners: Midatech Pharma plc; Immunotope Inc....
BioCentury | Jul 26, 2010
Product Development

Gold-plating Antigens

...Midatech Ltd. and partner Immunotope Inc. think they have a better way to raise an immune response...
...focus on the development of therapeutic vaccines to treat chronic viral infections and certain cancers. Immunotope...
...and know-how for its nanoparticle delivery technology. According to Ramila Philip, president and CSO of Immunotope...
BioCentury | Jul 19, 2010
Company News

Immunotope, Midatech deal

...treat chronic viral infections and cancer. Midatech will license Syntara IP related to nanomedicine, and Immunotope...
...the JV, which will be located in Doylestown, Pa. Midatech's lead nanomedicine compound is undisclosed. Immunotope's...
...twelve different antigens, which has completed Phase I testing to treat breast and ovarian cancers. Immunotope Inc....
BioCentury | Feb 15, 2010
Clinical News

DPX-0907: Phase I start

...breast, ovarian or prostate cancer. ImmunoVaccine has exclusive, worldwide rights to 7 cancer antigens from Immunotope Inc....
BioCentury | Jul 20, 2009
Company News

Immunotope, ImmunoVaccine Technologies deal

...ImmunoVaccine received exclusive, worldwide rights to seven of Immunotope's cancer antigens. ImmunoVaccine will combine the antigens...
...by year end. The DepoVax system uses liposomes to encapsulate a target antigen and adjuvant. Immunotope...
...and royalties. The license replaces a 2007 memorandum of understanding for ImmunoVaccine to acquire Immunotope. Immunotope Inc....
BioCentury | May 26, 2008
Finance

Ebb & Flow

...complete its already announced acquisition of Immunotope and to complete two Phase I trials of Immunotope's...
...price. The deal would combine ImmunoVaccine's VacciMax liposome stabilization technology for enhancing antibody production with Immunotope's...
BioCentury | Dec 17, 2007
Company News

Immunotope, ImmunoVaccine Technologies deal

...ImmunoVaccine will acquire Immunotope for an undisclosed price. The deal will combine ImmunoVaccine's VacciMax liposome stabilization...
...antibody production with Immunotope's portfolio of immunotherapeutic antigens and antigen discovery platform. ImmunoVaccine will continue Immunotope's...
...to treat ovarian and breast cancer. The deal is expected to close by June 2008. Immunotope Inc....
BioCentury | Mar 12, 2007
Company News

Immunotope board of directors update

Immunotope Inc. , Doylestown, Penn. Business: Cancer, Infectious Appointed: Elizabeth Tallett, a principal at Hunter Partners LLC WIR Staff cancer Infectious...
BioCentury | Mar 12, 2007
Company News

Immunotope management update

Immunotope Inc. , Doylestown, Penn. Business: Cancer, Infectious Hired: Edward Erickson, an industry consultant, as interim CEO and a director WIR Staff...
BioCentury | Aug 29, 2005
Clinical News

OCPM ovarian immunotherapeutic vaccine: IND submitted

...Immunotope submitted an IND to begin a U.S. Phase I trial before year end. Immunotope Inc....
Items per page:
1 - 10 of 11
BioCentury | May 25, 2018
Emerging Company Profile

Universal ambitions

...time and cost of traditional vaccine development. Emergex launched in 2016 with IP acquired from Immunotope Inc....
...infection and now has long-term CD8+ memory,” Rademacher said. In a 2014 paper describing the Immunotope...
...2016 by Thomas Rademacher and Storme Moore-Thornicroft University collaborators: Undisclosed Corporate partners: Midatech Pharma plc; Immunotope Inc....
BioCentury | Jul 26, 2010
Product Development

Gold-plating Antigens

...Midatech Ltd. and partner Immunotope Inc. think they have a better way to raise an immune response...
...focus on the development of therapeutic vaccines to treat chronic viral infections and certain cancers. Immunotope...
...and know-how for its nanoparticle delivery technology. According to Ramila Philip, president and CSO of Immunotope...
BioCentury | Jul 19, 2010
Company News

Immunotope, Midatech deal

...treat chronic viral infections and cancer. Midatech will license Syntara IP related to nanomedicine, and Immunotope...
...the JV, which will be located in Doylestown, Pa. Midatech's lead nanomedicine compound is undisclosed. Immunotope's...
...twelve different antigens, which has completed Phase I testing to treat breast and ovarian cancers. Immunotope Inc....
BioCentury | Feb 15, 2010
Clinical News

DPX-0907: Phase I start

...breast, ovarian or prostate cancer. ImmunoVaccine has exclusive, worldwide rights to 7 cancer antigens from Immunotope Inc....
BioCentury | Jul 20, 2009
Company News

Immunotope, ImmunoVaccine Technologies deal

...ImmunoVaccine received exclusive, worldwide rights to seven of Immunotope's cancer antigens. ImmunoVaccine will combine the antigens...
...by year end. The DepoVax system uses liposomes to encapsulate a target antigen and adjuvant. Immunotope...
...and royalties. The license replaces a 2007 memorandum of understanding for ImmunoVaccine to acquire Immunotope. Immunotope Inc....
BioCentury | May 26, 2008
Finance

Ebb & Flow

...complete its already announced acquisition of Immunotope and to complete two Phase I trials of Immunotope's...
...price. The deal would combine ImmunoVaccine's VacciMax liposome stabilization technology for enhancing antibody production with Immunotope's...
BioCentury | Dec 17, 2007
Company News

Immunotope, ImmunoVaccine Technologies deal

...ImmunoVaccine will acquire Immunotope for an undisclosed price. The deal will combine ImmunoVaccine's VacciMax liposome stabilization...
...antibody production with Immunotope's portfolio of immunotherapeutic antigens and antigen discovery platform. ImmunoVaccine will continue Immunotope's...
...to treat ovarian and breast cancer. The deal is expected to close by June 2008. Immunotope Inc....
BioCentury | Mar 12, 2007
Company News

Immunotope board of directors update

Immunotope Inc. , Doylestown, Penn. Business: Cancer, Infectious Appointed: Elizabeth Tallett, a principal at Hunter Partners LLC WIR Staff cancer Infectious...
BioCentury | Mar 12, 2007
Company News

Immunotope management update

Immunotope Inc. , Doylestown, Penn. Business: Cancer, Infectious Hired: Edward Erickson, an industry consultant, as interim CEO and a director WIR Staff...
BioCentury | Aug 29, 2005
Clinical News

OCPM ovarian immunotherapeutic vaccine: IND submitted

...Immunotope submitted an IND to begin a U.S. Phase I trial before year end. Immunotope Inc....
Items per page:
1 - 10 of 11